Highlights include a link between migraines and T2DM risk in women; fasting-evoked hypoglycemia being overlooked; and how gut microbiome influences the metabolism of diabetes drugs.
Surge in New GLP-1 Prescriptions Driven by Semaglutide's Popularity, Study Shows
Diabetes Dialogue: CATALYST Trial and Hypercortisolism in T2D, with John Buse, MD, PhD
FDA Issues Complete Response Letter for Once-Weekly Insulin Icodec
Diabetes Dialogue: ADA 2024 Diabetes Technology Recap
SGLT2 Inhibitor, GLP-1 RA Combination Improves Cardiovascular, Kidney Outcomes in Diabetes
Tirzepatide Bests Semaglutide in Real-World Weight Loss Analysis